Despite an urgent need for a universal flu vaccine there is no such vaccine in the market and no regulatory guideline for its approval. This special report from Future Virology proposes a stepwise process for regulatory and marketing approval for such a vaccine and discusses the epitope-based vaccine candidate Multimeric-001 (M-001).
The first study to investigate attitudes to the child flu vaccine in the UK has reported that concerns around the vaccines safety, efficiency and side effects may be reducing uptake.
Influenza, immunopathogenesis, and the interface of research and policy – an interview with Peter Openshaw
We at Infectious Diseases Hub recently spoke to Peter Openshaw, Professor of Experimental Medicine at Imperial College London (UK), about his research into respiratory viruses and the challenges currently facing science policy and funding.
The National Institutes of Health (MD, USA) have begun a Phase I clinical trial examining a vaccine intended to provide broad protection against a range of mosquito-borne diseases by targeting the insect’s saliva.
In this exclusive opinion piece, Danielle Stanisic (Griffith University, Australia) gives us her thoughts on the advantages of whole-parasite vaccines and discusses her work on this novel vaccine approach.
Researchers have demonstrated that a new whole-parasite vaccine could provide up to 100% protection in clinical trials carried out at the University of Tübingen (Germany).
Researchers have created a model to assess the benefits of vaccination on the burden of non-typhoidal salmonella in Mali; the research could inform policy in many countries where there is high risk of these infections.
Researchers have pioneered an mRNA-based vaccine against Zika that has demonstrated promising results in pre-clinical trials on mice and monkeys.
Vaccines against chikungunya, Zika and other emerging Aedes mosquito-borne viruses: unblocking existing bottlenecks
In this review the author looks at the progress of vaccine development towards mosquito-borne viral diseases, such as Zika and chikungunya.
Could one vaccine dose be as effective as two or three doses at preventing persistent HPV infection in the cervix in young women? This review discusses HPV vaccine coverage and the possibility of a one-dose schedule.